• Je něco špatně v tomto záznamu ?

Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM study

P. Bader, U. Pötschger, JH. Dalle, LM. Moser, A. Balduzzi, M. Ansari, J. Buechner, T. Güngör, M. Ifversen, G. Krivan, H. Pichler, M. Renard, R. Staciuk, P. Sedlacek, J. Stein, JR. Heusel, T. Truong, J. Wachowiak, A. Yesilipek, F. Locatelli, C. Peters

. 2024 ; 8 (2) : 416-428. [pub] 20240123

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007535

Allogeneic hematopoietic stem cell transplantation (HSCT) is highly effective for treating pediatric high-risk or relapsed acute lymphoblastic leukemia (ALL). For young children, total body irradiation (TBI) is associated with severe late sequelae. In the FORUM study (NCT01949129), we assessed safety, event-free survival (EFS), and overall survival (OS) of 2 TBI-free conditioning regimens in children aged <4 years with ALL. Patients received fludarabine (Flu), thiotepa (Thio), and either busulfan (Bu) or treosulfan (Treo) before HSCT. From 2013 to 2021, 191 children received transplantation and were observed for ≥6 months (median follow-up: 3 years). The 3-year OS was 0.63 (95% confidence interval [95% CI], 0.52-0.72) and 0.76 (95% CI, 0.64-0.84) for Flu/Thio/Bu and Flu/Thio/Treo (P = .075), respectively. Three-year EFS was 0.52 (95% CI, 0.41-0.61) and 0.51 (95% CI, 0.39-0.62), respectively (P = .794). Cumulative incidence of nonrelapse mortality (NRM) and relapse at 3 years were 0.06 (95% CI, 0.02-0.12) vs 0.03 (95% CI: <0.01-0.09) (P = .406) and 0.42 (95% CI, 0.31-0.52) vs 0.45 (95% CI, 0.34-0.56) (P = .920), respectively. Grade >1 acute graft-versus-host disease (GVHD) occurred in 29% of patients receiving Flu/Thio/Bu and 17% of those receiving Flu/Thio/Treo (P = .049), whereas grade 3/4 occurred in 10% and 9%, respectively (P = .813). The 3-year incidence of chronic GVHD was 0.07 (95% CI, 0.03-0.13) vs 0.05 (95% CI, 0.02-0.11), respectively (P = .518). In conclusion, both chemotherapeutic conditioning regimens were well tolerated and NRM was low. However, relapse was the major cause of treatment failure. This trial was registered at www.clinicaltrials.gov as #NCT01949129.

CANSEARCH Research Platform for Pediatric Oncology and Hematology Faculty of Medicine Department of Pediatrics Gynecology and Obstetrics University of Geneva Switzerland

Copenhagen University Hospital Rigshospitalet Department for Pediatric Hematology and Oncology Copenhagen Denmark

Department of Hematology Oncology Immunology Gene Therapy and Stem Cell Transplantation University Children's Hospital Zürich Eleonore Foundation and Children's Research Center Zürich Switzerland

Department of Paediatric Oncology University Hospital Leuven Leuven Belgium

Department of Pediatric Hematology and Oncology Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Pediatrico Bambino Gesù Catholic University of the Sacred Heart Rome Italy

Department of Pediatric Hematology and Oncology Motol University Hospital Prague Czech Republic

Department of Pediatric Hematology and Oncology Oslo University Hospital Oslo Norway

Department of Pediatric Oncology Hematology and Transplantology Poznań University of Medical Sciences Poznań Poland

Division of Pediatric Oncology and Cellular Therapy Alberta Children's Hospital Calgary Alberta Canada

Division of Pediatric Oncology and Hematology Department of Women Child and Adolescent University Geneva Hospitals Geneva Switzerland

Goethe University University Hospital Department of Pediatrics Division for Stem Cell Transplantation Immunology and Intensive Care Medicine Frankfurt Germany

Hospital de Pediatría Prof Dr Juan P Garrahan Buenos Aires Buenos Aires Argentina

Medical Park Antalya Hospital Antalya Turkey

Pediatric Hematology and Immunology Department Robert Debré Hospital Groupe Hospitalo Universitaire Assistance Publique Hôpitaux de Paris Nord Université Paris Cité Paris France

Pediatric Hematology and Stem Cell Transplantation Department Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases Budapest Hungary

Schneider Children's Medical Center of Israel and Sackler Faculty of Medicine Tel Aviv University Petah Tikva Israel

St Anna Children's Cancer Research Institute Vienna Austria

St Anna Children's Hospital University Vienna Vienna Austria

Università degli Studi di Milano Fondazione FONDAZIONE MONZA E BRIANZA PER IL BAMBINO E LA SUA MAMMA Department for Pediatric Hematology and Oncology Monza Italy

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007535
003      
CZ-PrNML
005      
20240423160037.0
007      
ta
008      
240412s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/bloodadvances.2023010591 $2 doi
035    __
$a (PubMed)37738088
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bader, Peter $u Goethe University, University Hospital, Department of Pediatrics, Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine, Frankfurt, Germany $1 https://orcid.org/0000000345540265
245    10
$a Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM study / $c P. Bader, U. Pötschger, JH. Dalle, LM. Moser, A. Balduzzi, M. Ansari, J. Buechner, T. Güngör, M. Ifversen, G. Krivan, H. Pichler, M. Renard, R. Staciuk, P. Sedlacek, J. Stein, JR. Heusel, T. Truong, J. Wachowiak, A. Yesilipek, F. Locatelli, C. Peters
520    9_
$a Allogeneic hematopoietic stem cell transplantation (HSCT) is highly effective for treating pediatric high-risk or relapsed acute lymphoblastic leukemia (ALL). For young children, total body irradiation (TBI) is associated with severe late sequelae. In the FORUM study (NCT01949129), we assessed safety, event-free survival (EFS), and overall survival (OS) of 2 TBI-free conditioning regimens in children aged <4 years with ALL. Patients received fludarabine (Flu), thiotepa (Thio), and either busulfan (Bu) or treosulfan (Treo) before HSCT. From 2013 to 2021, 191 children received transplantation and were observed for ≥6 months (median follow-up: 3 years). The 3-year OS was 0.63 (95% confidence interval [95% CI], 0.52-0.72) and 0.76 (95% CI, 0.64-0.84) for Flu/Thio/Bu and Flu/Thio/Treo (P = .075), respectively. Three-year EFS was 0.52 (95% CI, 0.41-0.61) and 0.51 (95% CI, 0.39-0.62), respectively (P = .794). Cumulative incidence of nonrelapse mortality (NRM) and relapse at 3 years were 0.06 (95% CI, 0.02-0.12) vs 0.03 (95% CI: <0.01-0.09) (P = .406) and 0.42 (95% CI, 0.31-0.52) vs 0.45 (95% CI, 0.34-0.56) (P = .920), respectively. Grade >1 acute graft-versus-host disease (GVHD) occurred in 29% of patients receiving Flu/Thio/Bu and 17% of those receiving Flu/Thio/Treo (P = .049), whereas grade 3/4 occurred in 10% and 9%, respectively (P = .813). The 3-year incidence of chronic GVHD was 0.07 (95% CI, 0.03-0.13) vs 0.05 (95% CI, 0.02-0.11), respectively (P = .518). In conclusion, both chemotherapeutic conditioning regimens were well tolerated and NRM was low. However, relapse was the major cause of treatment failure. This trial was registered at www.clinicaltrials.gov as #NCT01949129.
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a lidé $7 D006801
650    12
$a busulfan $x analogy a deriváty $7 D002066
650    12
$a nemoc štěpu proti hostiteli $x etiologie $7 D006086
650    12
$a transplantace hematopoetických kmenových buněk $x škodlivé účinky $7 D018380
650    12
$a akutní lymfatická leukemie $x etiologie $7 D054198
650    _2
$a recidiva $7 D012008
650    _2
$a thiotepa $x terapeutické užití $7 D013852
650    _2
$a příprava pacienta k transplantaci $x škodlivé účinky $7 D019172
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pötschger, Ulrike $u St. Anna Children's Cancer Research Institute, Vienna, Austria
700    1_
$a Dalle, Jean-Hugues $u Pediatric Hematology and Immunology Department, Robert Debré Hospital, Groupe Hospitalo-Universitaire Assistance Publique Hôpitaux de Paris (GHU AP-HP) Nord, Université Paris Cité, Paris, France
700    1_
$a Moser, Laura M $u Goethe University, University Hospital, Department of Pediatrics, Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine, Frankfurt, Germany
700    1_
$a Balduzzi, Adriana $u Università degli Studi di Milano-Fondazione, FONDAZIONE MONZA E BRIANZA PER IL BAMBINO E LA SUA MAMMA (MBBM), Department for Pediatric Hematology and Oncology, Monza, Italy $1 https://orcid.org/0000000258790610
700    1_
$a Ansari, Marc $u CANSEARCH Research Platform for Pediatric Oncology and Hematology, Faculty of Medicine, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Switzerland $u Division of Pediatric Oncology and Hematology, Department of Women, Child and Adolescent, University Geneva Hospitals, Geneva, Switzerland
700    1_
$a Buechner, Jochen $u Department of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo, Norway $1 https://orcid.org/0000000158484501
700    1_
$a Güngör, Tayfun $u Department of Hematology/Oncology/Immunology, Gene Therapy, and Stem Cell Transplantation, University Children's Hospital Zürich, Eleonore Foundation & Children's Research Center, Zürich, Switzerland $1 https://orcid.org/0000000232611186
700    1_
$a Ifversen, Marianne $u Copenhagen University Hospital Rigshospitalet, Department for Pediatric Hematology and Oncology, Copenhagen, Denmark
700    1_
$a Krivan, Gergely $u Pediatric Hematology and Stem Cell Transplantation Department, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary
700    1_
$a Pichler, Herbert $u St. Anna Children's Hospital, University Vienna, Vienna, Austria $1 https://orcid.org/0000000151075123
700    1_
$a Renard, Marleen $u Department of Paediatric Oncology, University Hospital Leuven, Leuven, Belgium
700    1_
$a Staciuk, Raquel $u Hospital de Pediatría "Prof. Dr. Juan P. Garrahan," Buenos Aires, Buenos Aires, Argentina
700    1_
$a Sedlacek, Petr $u Department of Pediatric Hematology and Oncology, Motol University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000178952886 $7 xx0037062
700    1_
$a Stein, Jerry $u Schneider Children's Medical Center of Israel and Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel
700    1_
$a Heusel, Jan Robert $u Goethe University, University Hospital, Department of Pediatrics, Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine, Frankfurt, Germany $1 https://orcid.org/0000000257530817
700    1_
$a Truong, Tony $u Division of Pediatric Oncology and Cellular Therapy, Alberta Children's Hospital, Calgary, Alberta, Canada
700    1_
$a Wachowiak, Jacek $u Department of Pediatric Oncology, Hematology and Transplantology, Poznań University of Medical Sciences, Poznań, Poland
700    1_
$a Yesilipek, Akif $u Medical Park Antalya Hospital, Antalya, Turkey
700    1_
$a Locatelli, Franco $u Department of Pediatric Hematology and Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Pediatrico Bambino Gesù, Catholic University of the Sacred Heart, Rome, Italy
700    1_
$a Peters, Christina $u St. Anna Children's Cancer Research Institute, Vienna, Austria $u St. Anna Children's Hospital, University Vienna, Vienna, Austria $1 https://orcid.org/0000000303698515
773    0_
$w MED00194912 $t Blood advances $x 2473-9537 $g Roč. 8, č. 2 (2024), s. 416-428
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37738088 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423160033 $b ABA008
999    __
$a ok $b bmc $g 2081500 $s 1217302
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 8 $c 2 $d 416-428 $e 20240123 $i 2473-9537 $m Blood advances $n Blood Adv $x MED00194912
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace